During the study, 27 out of 59 BRAF mutated NSCLC patients experienced partial response or complete response with an ORR of 45.8%, and 118 out of 358 WT BRAF NSCLC patients had a partial response or complete response with an ORR of 33.0%, indicating a comparable response rate between these two groups of NSCLC patients (p = 0.056). This evidence concerns the gene BRAF and non-small cell lung carcinoma.